JHMI J11136 A Phase 1 Study of BMS936558 Plus Sunitinib or Pazopanib in Subjects with Metastatic Renal Cell Carcinoma

Description: 

Dose Escalation: RCC with a clear-cell component or non-clear-cell RCC limited to papillary, chromophobe or unclassified histology; advanced or metastatic; measurable dx; at least 1 prior systemic therapy for mets (at least 1 prior cytokine, anti-angiogenic or mTOR inhibitor);  MUST have tumor tissue; NO active CNS mets

Link:

http://clinicaltrials.gov/ct2/show/NCT01472081

Site:

Johns Hopkins Hospital

Principal Investigator:

Hans Hammers, M.D.